e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bedaquiline: how better to use it
Jose A. Caminero, Alberto Piubello, Anna Scardigli, Giovanni Battista Migliori
Source:
Eur Respir J, 50 (5) 1701670; 10.1183/13993003.01670-2017
Journal Issue:
November
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jose A. Caminero, Alberto Piubello, Anna Scardigli, Giovanni Battista Migliori. Bedaquiline: how better to use it. Eur Respir J, 50 (5) 1701670; 10.1183/13993003.01670-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use
Source: Eur Respir J 2014; 43: 289-292
Year: 2004
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance
Source: Eur Respir J 2012; 39: 802-804
Year: 2012
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit?
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Investigating the steroids and long-acting β2-agonists combination: why do we need more?
Source: Eur Respir J 2004; 23: 501-502
Year: 2004
The goal is to go further and do better: but how?
Source: Eur Respir Rev 2015; 25: 1-3
Year: 2016
Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes
Source: Virtual Congress 2021 – Wheezing illnesses along the life span
Year: 2021
Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation?
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
Does combination therapy lead to better adherence in asthma?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Long-term oral antibiotic treatment: why, what, when and to whom?
Source: Eur Respir Monogr 2017; 75: 185-205
Year: 2017
Do technologies make a difference in adherence to treatment: instant messaging application use?
Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine
Year: 2020
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß
2
-agonist use in asthma
Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019
Year: 2020
New short regimens for latent tuberculosis treatment: safety first!
Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018
Year: 2018
Four-month regimens: are they feasible?
Source: International Congress 2015 – Tuberculosis: short-course chemotherapy
Year: 2015
Aiming for total control in asthma: an ineffective use of resources?
Source: Eur Respir J 2005; 26: Suppl. 49, 429s
Year: 2005
TB following targeted and biological therapy: can we predict it?
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020
Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
Source: Eur Respir J 2016; 47: 664-667
Year: 2016
Biodiesel: is it any safer to use?
Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation
Year: 2018
Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment
Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Year: 2007
The MABA approach: a new option to improve bronchodilator therapy
Source: Eur Respir J 2013; 42: 885-887
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept